Monopar Therapeutics

$5.31
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.16 (+3.11%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell MNPR and other stocks, options, and ETFs commission-free!

About MNPR

Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The firm engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages.

CEO
Chandler Drew Robinson
Employees
10
Headquarters
Wilmette, Illinois
Founded
2014
Market Cap
69.47M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
383.29K
High Today
$5.50
Low Today
$5.13
Open Price
$5.13
Volume
26.27K
52 Week High
$17.01
52 Week Low
$4.28

MNPR Earnings

-$0.19
-$0.13
-$0.06
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 6, Pre-Market

You May Also Like

EBACU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure